Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 12/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.70 |
| ▸ | HTR2A | P28223 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235499 | 0.92 | KCNJ1 (0.66) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL2731306 | 0.86 | KCNJ1 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL5151630 | 0.86 | KCNJ1 (0.70) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL3159579 | 0.85 | KDM4E (0.67) | KCNJ1SIGMAR1 | |
| SCHEMBL14786379 | 0.85 | HTR2A (0.72) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL14785737 | 0.84 | KCNJ1 (0.72) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL9234853 | 0.83 | HRH3 (0.68) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL1405964 | 0.83 | KCNJ1 (0.70) | KCNJ1KCNH2HRH3HTR2ASIGMAR1 | |
| SCHEMBL5653299 | 0.83 | HRH3 (0.93) | KCNJ1KCNH2HRH3SIGMAR1MAOA | |
| SCHEMBL3156895 | 0.83 | HRH3 (1.00) | KCNJ1KCNH2HRH3SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| WO-2007018941-A2 | PYRIMIDYL-THIOPHENE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-0649838-A1 | N-phenylalkyl/phenoxyalkyl-azetidine/pyrrozidinel piperidine/hexahydroazepine derivatives as antiarrhythmic agents | MERCK PATENT GmbH (DE) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194561-A1 | carboxyamide thiophenes and medicaments containing the same as well as processes for the preparation and use of such compounds, compositions and medicaments, particularly in diseases associated with inappropriate Aurora activity. | AURKA, AURKC, AURKB | KCNJ1 1906/4885KCNH2 3087/4885HRH3 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.